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Background
Approximately 5 to10% of FMF patients do not respond
and/or intolerant to to colchicine treatment. Several
case reports and case series have pointed out the effi-
cacy of IL-1 blockade in colchicine resistant FMF
subgroup.
Objectives
To review the patients followed in our center with FMF
who received anakinra, an anti IL-1 receptor antagonist,
because of insufficient colchicine response.
Methods
FMF patients who were treated with anakinra were ret-
rospectively reviewed with regard to indication, efficacy
and adverse events. Patient global assessment was
recorded before and throughout anakinra treatment.
Results
There were 36 FMF patients with FMF who were trea-
ted with anakinra for various indications (amyloidosis in
11, colchicine resistant recurrent febrile attacks in 21,
colchicine related side effects in 4). Two patients were
excluded since they have been on anakinra for less than
one month (one with amyloidosis, one pregnant). The
mean age of the group was 34.8±10.8 years. The mean
duration of the disease was 22.8 ±10,7 years. There were
various co-existing pathologies among this study group
like multiple sclerosis (1), ankylosing spondylitis (1),
SLE (1), Behçet’s disease (1), low grade lymphoma (1)
and PAN (2). Five patients received anakinra during
pregnancy. The mean colchicine dose was 2,09±0,49
mg/d. The mean duration of anakinra treatment was
13,34± 13,26 months. Twenty seven patients reported
no attacks after the initiation of anakinra treatment
whereas 5 patients reported at least 50% decrease in the
attack frequency. Mean patient global assessment
decreased from 8,74±2,2 to 1,74±2,6 under anakinra
treatment (p=0.001).
Among the 9 patients with amyloidosis, anakinra was
stopped in 2 patients because of increased proteinuria.
However, a significant decrease in proteinuria was
detected in 4 patients. Overall, 6 of our patients with
amyloidosis are still on Anakinra treatment.
The treatment was stopped due to severe allergic reac-
tions in 3 patients (severe disseminated rash in 1 and
severe injection site reaction in 2) and because of infec-
tions in 2 patients (genital warts and urinary tract infec-
tion in 1 and sinusitis and folliculitis in 1). One of our
patients reported that her psoriatic lesions got worse on
anakinra. Twenty six patients reported no adverse events.
Conclusions
Anakinra seems to be an effective and safe alternative in
patients who have insufficient response to colchicine as
well as in FMF related amyloidosis. The major cause of
treatment termination is injection site reactions.
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